Our cytotoxicity experiment data show that tivantinib significantly and in a dose-dependent manner inhibits cell proliferation in all six NB cell lines irrespective of their MYCN status while having a minimum effect on any fibroblast cell lines used (Figure 2). Here, MYCN is linked to neuroblastoma.